Stocktoria

Vera Therapeutics, Inc. VERA

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-05-14

Vera Therapeutics, Inc. financials (annual)

Revenue
202020212022202320242025
Net income
-$53.4M -$32.6M -$89.1M -$96.0M -$152.1M -$299.6M 202020212022202320242025
Free cash flow
-$34.9M -$23.7M -$67.7M -$92.2M -$135.7M -$241.7M 202020212022202320242025

Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020
R&D expense$215.3M$126.2M$78.2M$69.0M$22.5M$45.2M
Operating income-$315.5M-$167.2M-$102.0M-$90.9M-$34.4M-$52.2M
Interest expense$3.8M$992,000$20,000$166,000
Income tax$1,000$1,000$1,000$1,000$1,000-$1,000
Net income-$299.6M-$152.1M-$96.0M-$89.1M-$32.6M-$53.4M
EPS (diluted)$-4.66$-2.75$-2.25$-3.35$-2.43
Operating cash flow-$241.1M-$134.7M-$92.2M-$67.6M-$23.7M-$34.8M
Free cash flow-$241.7M-$135.7M-$92.2M-$67.7M-$23.7M-$34.9M
Cash & equivalents$354.7M$92.6M$45.7M$43.5M$79.7M$53.7M
Total assets$734.7M$655.7M$175.5M$131.4M$83.7M$54.6M
Total liabilities$130.2M$78.5M$73.9M$54.5M$14.2M$4.3M
Shareholders' equity$604.5M$577.2M$101.7M$76.9M$69.6M-$89.3M

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.